What's the difference between several vaccines vaccinated in China and Canada? Which is better?

Health Canada has authorized the use of four different types of COVID-19 vaccines produced by Ffizer-BioNTech, Moderna, AstraZeneca (AZ) and Johnson & Johnson.

Recently, the World Health Organization (WHO) will announce whether to authorize the emergency application of China Sinopharm, Kexing and Madena COVID-19 vaccines. At this stage, the purpose of these rules is to open up an accelerated and safe passage for pre-seedlings to enter all parts of the world, and to promote the vaccination contained in the rules more effectively and comprehensively on a global scale; Now this list includes Pfizer, AstraZeneca and Johnson & Johnson/Li Yong Pre-vaccine.

As we all know, Pfizer BioNTech and Moderna pre-vaccines use mRNA technology, while AZ and single-dose Johnson & Johnson vaccine are pre-vaccines based on viral vectors. As we all know, China vaccination is generally used for vaccination. For example, Chinese medicine vaccine and Kexing pre-vaccine are both live vaccines, and two doses must be injected, which are basically preserved at low temperature.

According to the viral vector pre-vaccine (such as AZ, pre-vaccine developed by Johnson & Johnson Company), the viral vector pre-vaccine spreads by live virus infection or parainfluenza virus, which opens the human immune system and makes it produce antibodies to resist COVID-19 infection caused by novel coronavirus.

Health Canada explained on the platform that parainfluenza virus was not novel coronavirus itself, but was infected by other harmless viruses through transformation, so it could not be replicated in the body and caused diseases. Parainfluenza virus is a virus that causes the common cold. There are many different types, and it has been used to obtain protein produced by vaccines for decades.

As far as COVID-19 vaccine is concerned, vector virus infection transfers the genetic sequence of specific genes to somatic cells in vivo, resulting in harmless novel coronavirus, which is called protein. Subsequently, somatic cells produce this spike protein, which turns on the response of the human immune system. Then, the human immune system produces an antigen against protein, a thorn, to resist what it calls allergic diseases. If the human immune system encounters real novel coronavirus virus infection and protein in the future, my body will have the defense against the original and develop its defense.

The pre-vaccine that depends on the virus vector is genetically modified, so it cannot be replicated, which means that once the antibody is produced, the virus vector that entered the body before is completely solved.

According to the Centers for Disease Control and Prevention (CDC), the advantage of pre-vaccination with virus vectors is that they can provide protection against novel coronavirus, and there is no need to put them into action to breed antibodies in COVID-19. This pre-vaccine uses safe virus infection to deliver the special components of the whole target microbial species (called protein), so that it can start the immune response without causing disease.

The Centers for Disease Control and Prevention also stressed that this pre-vaccine is not easy to really infect COVID-19, nor can parainfluenza virus be used as a pre-vaccine culture medium. To this end, a special part of the whole target pathogen produced and manufactured is inserted into a safe virus infection. Subsequently, safe virus infection can be used as a service platform or medium to deliver special protein to human body. This protein will trigger an immune response. Ebola vaccine is a viral vector pre-vaccine, and this type of pre-vaccine can be developed and designed quickly.